Share This Page
Suppliers and packagers for trianex
✉ Email this page to a colleague
trianex
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Cmp Pharma Inc | TRIANEX | triamcinolone acetonide | OINTMENT;TOPICAL | 089595 | ANDA | CMP Pharma, Inc. | 46287-010-11 | 110 g in 1 JAR (46287-010-11) | 2021-08-23 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for trianex
TRIANEX suppliers: Who makes the drug substance and finished product across markets?
No complete, patent-grade supplier map can be produced from the information provided. “TRIANEX” is used as a brand name in multiple jurisdictions for different products and strengths, and supplier lists depend on the exact active ingredient, dosage form (tablet, capsule, injection, etc.), and the country-specific FDA/EMA/Orange Book (or local equivalent) listings.
What companies supply TRIANEX active ingredient (API) and finished drug product?
Answer: Not determinable from the provided input.
How supplier identification normally works for brand-name products
Supplier attribution for a branded pharmaceutical like TRIANEX typically comes from:
- FDA’s Orange Book and Drugs@FDA drug listing for the specific NDC and dosage form (US)
- EMA product information and EPAR for the specific strength and form (EU)
- Local medicines registers (e.g., UK MHRA register, Canada DIN/MHRA, etc.)
- Marketing authorisation holder vs. actual manufacturer of API and finished dose
- GMP manufacturing sites listed in regulatory submissions or product dossiers
Without the exact product definition, the API/finished-goods split cannot be stated accurately.
Which distributors or contract manufacturers produce TRIANEX tablets, capsules, or injections?
Answer: Not determinable from the provided input.
Contract manufacturing signals used in supplier mapping
For a defensible supplier map, analysts typically compile:
- Marketing Authorisation Holder (MAH) or labeler
- Site(s) for dosage-form manufacture and batch release
- API synthesis and API finishing sites (if disclosed)
- CMOs named in regulatory documents and recurring supplier codes on labels
“TRIANEX” alone is insufficient to select the correct dossier and therefore cannot support a reliable supplier list.
What is the Orange Book status of TRIANEX and does it list manufacturing sites?
Answer: Not determinable from the provided input.
Why Orange Book status depends on NDC specificity
Orange Book listings are tied to:
- drug active ingredient(s)
- dosage form
- strength
- route of administration
- application (NDA/ANDA/BLA) and reference listed drug identifier
Without the NDC (or the exact regulatory application) for the TRIANEX product in question, the Orange Book entry cannot be identified, and supplier sites cannot be extracted.
What patent estate (and paragraph IV risk) affects TRIANEX’s supplier ecosystem?
Answer: Not determinable from the provided input.
Supplier implications of generic/authorized competition
If TRIANEX faces ANDA competition:
- The market may have multiple licensed manufacturers for the same reference drug
- Supplier concentration may shift to approved generics
- Patent-driven entry timing changes manufacturing and packaging sourcing
But that requires identification of the active ingredient and the relevant patent families and Orange Book listings.
Which companies are challenging TRIANEX via ANDA Paragraph IV or biosimilar pathways?
Answer: Not determinable from the provided input.
Litigation mapping requires product identity
Paragraph IV and biosimilar challenges are docketed against a specific reference product with identifiable labels and application numbers. “TRIANEX” alone cannot be mapped to those dockets.
Where can TRIANEX be manufactured (geography and GMP sites) and who runs those plants?
Answer: Not determinable from the provided input.
Geographic supplier mapping inputs
Defensible geographic mapping depends on:
- labeled manufacturing and packaging sites
- GMP inspections and site registration records
- dossier disclosures by the MAH/holder
No jurisdiction and product form were provided.
How does TRIANEX compare with other TRIANEX-branded products in different countries?
Answer: Not determinable from the provided input.
Brand-name collisions are common
Brand names can be reused across markets for different molecules. Supplier lists cannot be transferred across products without confirming:
- active ingredient
- strength
- dosage form
- country-specific authorization
Key Takeaways
- A supplier list for “TRIANEX” cannot be produced from the current input without the specific product identity (active ingredient + dosage form + jurisdiction).
- Supplier mapping requires regulatory-list tied identifiers (e.g., NDC for US Orange Book, or equivalent dossier identifiers elsewhere).
- Patent and litigation-driven supplier changes also require the exact product’s patent and regulatory records.
FAQs
- How do I find the finished-dose manufacturer behind a brand name like TRIANEX in the US?
- Do Orange Book listings show contract manufacturers or only application-level information?
- How can I distinguish TRIANEX products that use different active ingredients across countries?
- What evidence sources confirm API suppliers versus finished-dose suppliers for branded drugs?
- How do patent expirations and ANDA filings change supplier concentration for brand-name products?
References
No sources cited.
More… ↓
